title: Pharmacological characterization of putative beta1-beta2-adrenergic receptor heterodimers.
abstract: In the last few years, significant experimental evidence has accumulated showing that many G protein coupled receptors (GPCRs) are structurally and perhaps functionally homodimers. Recently, a number of studies have demonstrated that many GPCRs, notably GABA(B), somatostatin, and delta and kappa opioid receptors form heterodimers, as well. Based on these observations, we undertook a pharmacological and functional analysis of HEK 293 cells transiently transfected with the beta1AR or beta2AR or with both subtypes together. High-affinity binding for subtype-specific ligands (betaxolol and xamoterol for the beta1AR, and ICI 118,551 and procaterol for the beta2AR) was detected in cells expressing the cognate receptors alone with values similar to those reported in the literature. However, a significant portion of these high-affinity interactions were lost when both receptors were expressed together while nonspecific ligands (propranolol and isoproterenol) retained their normal affinities. When competition assays were performed with each subtype-specific ligand in the presence of a constant concentration of the other subtype-specific ligand, the high-affinity binding site was rescued, suggesting that the two receptor subtypes were interacting in a fashion consistent with positive cooperativity. Our data suggest that the beta1AR and beta2AR can form heterodimers and that these receptors have altered pharmacological properties from the receptor homodimers.
authors.affiliation: Centre de recherche, Institut de Cardiologie de Montréal, 5000 rue Bélanger est, Montréal, QC H1T 1C8, Canada.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lavoie
authors.forename: Terence E
authors.initials: TE
authors.lastname: Hébert
mesh_terms: D000262:Adenylyl Cyclases / Q000032:analysis* / Q000187:drug effects*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology*; D015153:Blotting, Western / Q000379:methods; D002478:Cells, Cultured; D019281:Dimerization; D066298:In Vitro Techniques; D008055:Lipids / Q000235:genetics; D051381:Rats; D018342:Receptors, Adrenergic, beta-1 / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D018343:Receptors, Adrenergic, beta-2 / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D014162:Transfection / Q000379:methods; D014170:Transformation, Genetic / Q000235:genetics
chemical_list: D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D008055:Lipids; C086724:Lipofectamine; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2; D000262:Adenylyl Cyclases